Shares of Retrophin Inc. (NASDAQ:RTRX) dropped 1.7% during mid-day trading on Friday . The company traded as low as $15.93 and last traded at $16.07, with a volume of 130,974 shares traded. The stock had previously closed at $16.35.

A number of equities analysts have recently commented on RTRX shares. Zacks Investment Research upgraded Retrophin from a “hold” rating to a “strong-buy” rating and set a $17.00 price objective on the stock in a report on Saturday, May 7th. Leerink Swann restated a “buy” rating on shares of Retrophin in a report on Wednesday, May 11th. BMO Capital Markets restated a “buy” rating on shares of Retrophin in a report on Monday, June 20th. Finally, JMP Securities restated a “buy” rating on shares of Retrophin in a report on Saturday, July 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $24.20.

The company has a market cap of $591.37 million and a price-to-earnings ratio of 6.54. The company’s 50 day moving average is $17.52 and its 200 day moving average is $16.22.

Retrophin (NASDAQ:RTRX) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.30. The company had revenue of $33.30 million for the quarter, compared to analyst estimates of $32.73 million. The firm’s revenue was up 38.2% compared to the same quarter last year. Analysts predict that Retrophin Inc. will post $0.09 earnings per share for the current year.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.